Gefitinib-resistant lung cancer cells having high levels of miR-21, miR-30b/c and miR-221/22, as consequence of c-MET overexpression, were rendered susceptible to gefitinib when treated with SU11274, a c-MET inhibitor.100. The gene discussed is MET; the disease is lung cancer.